Fierce Pharma

JULY 14, 2023

The potentially curative promise of gene therapies often carries a steep price tag. | The potentially curative promise of gene therapies often carries a steep price tag. But for a pair of personalized medicine prospects in sickle cell disease (SCD), the cost could be worth it, at least as far as ICER is concerned.

Prospecting 219

Prospecting Medicine 219

Pharmaceutical Technology

NOVEMBER 9, 2022

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. million price tag. The greater durability has also served as a factor in ICER giving EtranaDez a higher fair price estimate, says Rind.

Safety 111

Safety Pharmaceutical Patients Medicine 111

pharmaphorum

OCTOBER 3, 2022

Chief medical officer at the independent drug pricing watchdog, Institute for Clinical and Economic Review (ICER), David Rind said Relyvrio should have been priced closer to the cost of production until there is clear proof about its efficacy. The post Amylyx ALS drug draws criticism over $158,000 price tag appeared first on.

Insurance 52

Insurance Prescription FDA Patients 52

Pharmaceutical Technology

APRIL 13, 2023

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Still, comparing the two therapies remains difficult, with ICER rating the evidence as insufficient.

Healthcare 59

Healthcare Healthcare Pharmaceutical FDA 59

pharmaphorum

AUGUST 21, 2022

There’s no word yet on its pricing, but for comparison Spravato was launched with an annual price tag of around $32,400, which the Institute for Clinical and Economic Review (ICER) concluded was around 25% to 52% too high to be cost effective.

FDA 82

FDA Marketing Pharma Sales 82

pharmaphorum

AUGUST 18, 2022

million price tag attached to the therapy when it was first made available in Europe, and is also well above the proposed $2.1 million level that cost-effectiveness organisation ICER said would be acceptable in a July report. That payback option was also factored into the ICER review, though notably over a five-year period.

FDA 52

FDA Insurance Patients Medical 52

pharmaphorum

NOVEMBER 24, 2022

One issue has been the cost of the drug, with health technology assessment agency NICE in the UK and the ICER organisation in the US both concluding its price tag means it is not a cost-effective option for health systems.

Sales 52

Sales Patients Competition Marketing 52